ReviewESMO gastrointestinal oncology2024
Improving gastrointestinal cancer therapy by uniting stakeholders.
Review in ESMO gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal (GI) cancer-an umbrella term for cancers that affect the digestive system and other abdominal organs-includes some malignancies with the lowest survival rates. To improve patient outcomes, patients must have access to optimal treatment including precision oncology, a method of determining the most effective treatment for an individual cancer patient by identifying predictive biomarkers through the use of advanced molecular diagnostics. While many powerful molecular profiling technologies have already been developed, their uptake in the management of GI cancers could be improved. To bridge this gap, better coordination among three interdependent stakeholders-scientists, clinicians, and industry professionals-is essential. The first Translational and Precision GI-Oncology-Bench to Bedside Meeting was held on 23-28 April 2023 in Freiburg, Germany. The 3-day meeting offered the opportunity for scientists, clinicians, and industry professionals in the field of GI cancer to exchange ideas about how to improve the translation of basic science into clinical practice. One-hundred and twenty participants attended the meeting, which featured 47 presentations covering the following five topics: bedside, analytical approaches for treatment and real-world data, new ideas and biomarkers, novel technologies, and drugs. A summary of the 2023 meeting is provided in this report.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.